Chemotherapy-driven increases in the CDKN1A/PTN/PTPRZ1 axis promote chemoresistance by activating the NF-κB pathway in breast cancer cells

BACKGROUND: Chemotherapy is the primary established systemic treatment for patients with breast cancer, especially those with the triple-negative subtype. Simultaneously, the resistance of triple-negative breast cancer (TNBC) to chemotherapy remains a major clinical problem. Our previous study demon...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Peng, Ouyang, Deng-jie, Chang, Shi, Li, Mo-yun, Li, Lun, Li, Qian-ying, Zeng, Rong, Zou, Qiong-yan, Su, Juan, Zhao, Piao, Pei, Lei, Yi, Wen-jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267809/
https://www.ncbi.nlm.nih.gov/pubmed/30497491
http://dx.doi.org/10.1186/s12964-018-0304-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267809/
https://www.ncbi.nlm.nih.gov/pubmed/30497491
http://dx.doi.org/10.1186/s12964-018-0304-4

Ejemplares similares